There have been a mixed bag of observations regarding Bio-Rad Laboratories. Vanguard Group, Inc. and ICICI Prudential Asset Management Co Ltd significantly reduced their stock holdings amidst a slump in the share price. However, Assetmark Inc., Envestnet Asset Management Inc., and CenterBook Partners LP, have increased their holdings. Bio-Rad Laboratories' revenue shows modest growth and good free cash flow, but their Q4 earnings failed to meet estimates, causing a drop in stock prices. Both Q3 and Q4 earnings missed estimates with Q3 reporting a loss of US$12.70 EPS. This, along with rumors about a potential partnership with Biodesix, seems to be redefining the investment outlook for Bio-Rad Laboratories. Analysts have given a consensus recommendation of 'Hold', while others suggest 'reassessing' the investment after a multi-year share price weakness. The stock, however, continues to slip down, crossing below the 200-day moving average and prompting questions as to whether it's the time to sell or not. The long forecast for Bio-Rad Laboratories remains negative and current uncertainty seems to be hampering its potential.
Bio-Rad Laboratories Stocks News Analytics from Tue, 11 Oct 2022 07:00:00 GMT to Sat, 28 Feb 2026 15:48:09 GMT - Rating -5 - Innovation -2 - Information 2 - Rumor -4
